ライフサイエンスコーパス: NNT

1 NNT knockdown in a human adrenocortical cell line result

2 NNT makes a major contribution to peroxide metabolism du

3 NNT-1/BSF-3 cDNA was cloned from activated Jurkat human

4 NNT-1/BSF-3 induces tyrosine phosphorylation of glycopro

5 NNT-1/BSF-3 is a gp130 activator with B-cell stimulating

6 NNT-1/BSF-3 mRNA is found mainly in lymph nodes and sple

7 NNT-1/BSF-3 regulates immunity by stimulating B cell fun

8 NNT-1/BSF-3 shows activities typical of IL-6 family memb

9 NNT-1/BSF-3 stimulates B cell proliferation and Ig produ

10 NNT-1/BSF-3-transgenic mice also show non-amyloid mesang

11 NNT-1/BSF-3-transgenic mice produce high amounts of Ag-s

12 NNT-1/BSF-3-transgenic mice show high serum levels of Ig

13 NNT-1/BSF-3-transgenic mice, engineered to express NNT-1

14 NNTs were lower for tricyclic antidepressants, strong op

15 NNTs were lowest for MSM and transgender women self-repo

16 ity (RR, 0.64; 95% CI, 0.46 to 0.89; I2, 0%; NNT, 23) in patients receiving ventilation with lower ti

17 93), quetiapine (OR, 1.53, 95% CI, 1.17-2.0; NNT, 10), and risperidone (OR, 1.83, 95% CI, 1.16-2.88;

18 ontrol restorations, 38 (42%) (p < 0.000001; NNT 3).

19 ontrol restorations, 60 (46%) (p < 0.000001; NNT 3).

20 ontrol restorations, 22 (17%) (p = 0.000004; NNT 7); and 'Minor' failures, HT, 7 (5%); control restor

21 trol restorations, 15 (16.5%) (p = 0.000488; NNT 8); and 'Minor' failures (reversible pulpitis, resto

22 ors (RR, 0.63 [95% CI, 0.50-0.80]; P < .001; NNT, 105 [95% CI, 69-212]), 3 factors (RR, 0.54 [95% CI,

23 ears (RR, 0.84; 95% CI, 0.79-0.89; P < .001; NNT, 17).

24 ore (RR, 0.40 [95% CI, 0.25-0.73]; P < .001; NNT, 18 [95% CI, 12-34]).

25 year (RR, 0.77; 95% CI, 0.71-0.84; P < .001; NNT, 21) and 2 years (RR, 0.94; 95% CI, 0.89-1.00; P = .

26 year (RR, 0.66; 95% CI, 0.43-0.99; P < .001; NNT, 26).

27 est (RR, 0.67 [95% CI, 0.57-0.79]; P < .001; NNT, 339 [95% CI, 240-582]), again limited to patients u

28 ors (RR, 0.54 [95% CI, 0.39-0.73]; P < .001; NNT, 41 [95% CI, 28-80]), or 4 factors or more (RR, 0.40

29 the RR was 0.19 (95% CI, 0.06-0.53; P=.002; NNT, 15).

30 cardiac mortality (0.67, 0.51-0.89; p=0.006; NNT=347), with similar cardiac mortality (0.93, 0.73-1.1

31 ean (OR = 0.53; 95% CI: 0.33-0.87; P = 0.01; NNT = 30) and clean-contaminated surgery (OR = 0.43; 95%

32 NT, 5) and chronicity (chi2 = 7.46; P = .02; NNT, 6) such that the advantage for combined treatment w

33 ery (OR = 0.43; 95% CI: 0.20-0.93; P = 0.03; NNT = 9) specifically.

34 years (RR, 0.94; 95% CI, 0.89-1.00; P = .04; NNT, 593).

35 actions with severity (t451 = 1.97; P = .05; NNT, 5) and chronicity (chi2 = 7.46; P = .02; NNT, 6) su

36 83.7%; RR, 1.21; 95% CI, 1.00-1.46; P = .05; NNT, 6.9).

37 pregnated catheters (-1.98%, -3.90 to -0.06, NNT 51, 26-1667).

38 ssion at week 8 (RR, 4.5 [95% CI, 1.4-14.1]; NNT = 2.45; P = .01).

39 ized for a hospital threshold volume of 100 (NNT=50) and a surgeon threshold volume of 50 (NNT=118).

40 22-0.74; 1.17% [12/1024] vs 3.04% [31/1019]; NNT = 54).

41 54.8%; RR, 1.26; 95% CI, 0.95-1.68; P = .11; NNT, 6.9).

42 onths (RR, 0.72; 95% CI, 0.48-1.09; P = .12; NNT, 14) and 1 year (RR, 0.66; 95% CI, 0.43-0.99; P < .0

43 acebo/UC in terms of response rate (RR=0.22, NNT=2), delirium severity scales scores (SMD=-1.27), CGI

44 neurotrophin-1/B cell-stimulating factor-3 (NNT-1/BSF-3).

45 neurotrophin-1/B cell-stimulating factor-3 (NNT-1/BSF-3; also reported as cardiotrophin-like cytokin

46 on (RR, 0.45; 95% CI, 0.22 to 0.92; I2, 32%; NNT, 26), lower mean (SD) hospital length of stay (6.91

47 37.9%; RR, 1.21; 95% CI, 0.82-1.81; P = .35; NNT, 12.4) or at week 20 (69.3% vs 54.8%; RR, 1.26; 95%

48 RR=0.80, CI: 0.70-0.91, P=0.0007, I(2)=37%; NNT=17, CI: 10-50, P=0.003).

49 ause (OR 0.69, 0.62-0.78; ARR 2.7%, 2.0-3.5; NNT 37, 29-52), implying that 145 self-harm episodes and

50 vs 3/26 [11.5%]; RR, 4.0 [95% CI, 1.2-12.5]; NNT = 2.86; P = .01; and 25% response, 18/28 [64.2%] vs

51 NT=50) and a surgeon threshold volume of 50 (NNT=118).

52 3.96; P = .001; HR, 2.34; 95% CI, 1.54-3.57; NNT, 3; 95% CI, 2-5).

53 At P-6, NNT treatment decreased 5-HT levels slightly compared wi

54 elopment of HE (RR = 0.47, 95% CI 0.33-0.68, NNT = 6), the risk of developing serious liver-related a

55 renal syndrome (RR = 0.42, 95% CI 0.26-0.69, NNT = 50).

56 39-0.80; treatment-control difference, 1.7%; NNT, 60).

57 adverse events (RR = 0.48, 95% CI 0.33-0.70, NNT = 6), and reduced mortality (RR = 0.63, 95% CI 0.40-

58 bation failure (RR, 0.48; 95% CI, 0.32-0.71; NNT, 4; 95% CI, 2-7) compared with placebo or no treatme

59 : aripiprazole (OR, 2.07; 95% CI, 1.58-2.72; NNT, 7), OFC (OR, 1.30, 95% CI, 0.87-1.93), quetiapine (

60 40) or delayed antibiotics (0.61, 0.50-0.74; NNT 18).

61 nts (relative risk, 0.58; 95% CI, 0.44-0.77; NNT, 6; 95% CI, 4-13).

62 bation failure (RR, 0.70; 95% CI, 0.60-0.81; NNT, 8; 95% CI, 5-13).

63 physiotherapy (RR, 0.32; 95% CI, 0.13-0.82; NNT, 15; 95% CI, 7-50) both reduced extubation failure r

64 82.5%; RR, 1.01; 95% CI, 0.88-1.17; P = .84; NNT, 84).

65 nd risperidone (OR, 1.83, 95% CI, 1.16-2.88; NNT, 8).

66 cide (OR 0.75, 0.60-0.94; ARR 0.5%, 0.1-0.9; NNT 188, 108-725), and death by any cause (OR 0.69, 0.62

67 vs 8/26 [30.8%]; RR, 2.1 [95% CI, 1.1-3.9]; NNT = 2.99; P = .01).

68 with overt HE (RR = 0.36, 95% CI 0.14-0.94, NNT = 20), although not in patients with minimal HE.

69 also reduced by immediate (0.83, 0.73-0.94; NNT 40) or delayed antibiotics (0.61, 0.50-0.74; NNT 18)

70 orticosteroids (RR, 0.18; 95% CI, 0.04-0.97; NNT, 12; 95% CI, 6-100) and chest physiotherapy (RR, 0.3

71 uced mortality (RR = 0.63, 95% CI 0.40-0.98, NNT = 20).

72 rescription of antibiotics (0.58, 0.34-0.98; NNT 174).

73 the middle predicted benefit subgroup had a NNT of 76 (ARR = 0.013, 95% CI: -0.0001, 0.026; P = 0.05

74 of 0.91 (95% CI, 0.84-0.98), resulting in a NNT of 12 (95% CI, 7-78).

75 nt(-/-) exhibit approximately 50% and absent NNT activity, respectively, but the activities of concur

76 s with eGFR<30 ml/min per 1.73 m(2) Adjusted NNT (95% confidence interval) to avoid dialysis was 22.4

77 risk patients with LDL-C >/=70 mg/dl, and an NNT </=30 for very high-risk and high-risk patients with

78 isk patients with LDL-C >/=190 mg/dl, and an NNT </=30 for very high-risk patients with LDL-C >/=160

79 lower LDL-C by at least 50% would provide an NNT </=50 for very high-risk and high-risk patients with

80 d from 837 at year 10 to 503 at year 12, and NNT decreased from 29 to 18.

81 eptibility between NNT-deficient 6J mice and NNT-competent C57BL/6 substrains.

82 NNT 44 for PCI-related delay 60-90 min; and NNT 250 for PCI-related delay >90 min].

83 val study setting such as the ERSPC, NNS and NNT are time specific, and reporting values at one time

84 Although NNS and NNT are useful statistics to assess the benefits and har

85 According to our model, the NNS and NNT at 9 years were 1,254 and 43, respectively.

86 effect of varying follow-up times on NNS and NNT using data extrapolated from the ERSPC report.

87 Consideration of the PAF and NNT can aid in discussion of the benefits and risks of p

88 Poisson model, and we calculated the PAF and NNT for risk behaviour subgroups.

89 We aimed to estimate the PAF and NNT of participants in the iPrEx (Pre-Exposure Prophylax

90 Of 359 eligible articles, NNT was reported in 8 articles.

91 red metabolic disease susceptibility between NNT-deficient 6J mice and NNT-competent C57BL/6 substrai

92 imary measure and assessed publication bias; NNT was calculated with the fixed-effects Mantel-Haensze

93 re generally modest: in particular, combined NNTs were 6.4 (95% CI 5.2-8.4) for serotonin-noradrenali

94 receptive anal intercourse without a condom (NNT 36), cocaine use (12), or a sexually transmitted inf

95 Importantly, knocking down NNT inhibits reductive carboxylation in SkMel5 and 786-O

96 epidemiological impact (PIA) and efficiency (NNT) at plausible scale-up levels.

97 The estimated NNT for routine PPI use to prevent one disabling or fata

98 r were upper gastrointestinal, the estimated NNT for routine PPI use to prevent such bleeds is low, a

99 he seemingly simplistic nature of estimating NNT, there is widespread misunderstanding of its pitfall

100 ; number needed to treat to prevent 1 event [NNT], 48).

101 BSF-3-transgenic mice, engineered to express NNT-1/BSF-3 in the liver under control of the apolipopro

102 The gene for NNT-1/BSF-3 is on chromosome 11q13.

103 Our results demonstrate a novel role for NNT as a regulator of macrophage-mediated inflammatory r

104 ratio (RR), the number-needed-to-treat/harm (NNT/NNH), 95% CIs and standardised mean difference (SMD)

105 ve anal sex without a condom had the highest NNTs (100 and 77, respectively).

106 lementation studies showed that mutant human NNT failed to rescue nnt morpholino-induced heart dysfun

107 dentified, which shows 96% homology to human NNT-1/BSF-3.

108 In NNT-treated rats, the Di-I-labeled vibrissae-related pat

109 7BL/6J phenotype but the parameters of CP in NNT-expressing transgenic mice generated on a C57BL6/J b

110 mily, we identified a frameshift mutation in NNT, a nuclear-encoded mitochondrial protein, not implic

111 exome sequencing, we identified mutations in NNT, an antioxidant defense gene, in individuals with fa

112 OR 0.36, 0.26-0.50) in myocardial ischaemia (NNT 16) at the expense of an increase (OR 2.01, 1.27-3.6

113 times daily (5x/day), with either 0.1 mg/kg NNT or vehicle from birth to postnatal day 6 (P-6).

114 be defective in C57BL/6J mice, and no mature NNT protein could be detected.

115 es included regulators of energy metabolism (NNT), trafficking and membrane fusion (SLCO2A1 and ANXA7

116 reat (NNT) 23 for PCI-related delay >60 min; NNT 44 for PCI-related delay 60-90 min; and NNT 250 for

117 iority of SGAs regarding relapse was modest (NNT=17), but confirmed in double-blind trials, first- an

118 ther administration of 5-nonyloxytriptamine (NNT), a selective 5-HT(1B) receptor agonist, affects TCA

119 results indicate that the agonist action of NNT at the 5-HT(1B) receptor causes TCA disorganization

120 This action of NNT could explain its putative protective role in MnSOD-

121 kedly influence the relative contribution of NNT (i.e. varies between nearly 0 and 100%) to NADPH-dep

122 The contribution of NNT to peroxide metabolism is decreased during ADP phosp

123 Here, we show that knockdown of NNT inhibits the contribution of glutamine to the TCA cy

124 The lack of NNT activity in Nnt(-/-) mice impairs peroxide metabolis

125 variances in the 6J stain, including loss of NNT function, these findings suggest that the 6N substra

126 Overexpression of NNT in a macrophage cell-line resulted in decreased leve

127 Overexpression of NNT is sufficient to stimulate glutamine oxidation and r

128 The forward reaction of NNT, a nuclear-encoded mitochondrial inner membrane prot

129 Resequencing of NNT in additional LVNC families identified a second like

130 Our findings underscore the role of NNT in regulating central carbon metabolism via redox ba

131 authors expressed their findings in terms of NNT or ARR.

132 The overall NNT per year for the cohort was 62 (95% CI 44-147).

133 t doses must be administered to 12 patients (NNT, 12.2; 95% CI, 7.5 to 33.4) not receiving dexamethas

134 = 0.16; responder rate, 60% DES vs. 47% PLA; NNT, 8.1) but did show a statistically significant benef

135 = 0.01; responder rate, 73% DES vs. 49% PLA; NNT, 5.2), especially when participants with nondetectab

136 The predicted NNT for the guidelines would be 25.

137 d a very low event rate and a high projected NNT.

138 reporting methods (relative risk reduction, NNT, and ARR).

139 ed through pyruvate carboxylase and rendered NNT knockdown cells more sensitive to glucose deprivatio

140 0.39), and 0.55 (0.43-0.71), with respective NNTs of 4.1, 6.7, and 5.3.

141 methods are the nearest neighbor technique (NNT) and Moran's IPOP technique, a variation of Moran's

142 sulin resistance, coupled with the fact that NNT regulates peroxide detoxification, it was hypothesiz

143 We found that NNT mRNA is enriched in immune system-related tissues an

144 Our results suggest that NNT may have a role in ROS detoxification in human adren

145 udy, we demonstrated for the first time that NNT has a significant effect in the modulation of the im

146 The NNT to prevent return to any drinking for acamprosate wa

147 The NNT to prevent return to heavy drinking was 12 (95% CI,

148 The NNT was 14 (95% CI 8-50), suggesting that approximately

149 performance of the entropy technique and the NNT were independent of scale, that of Moran's IPOP was

150 For partial (>/=75%) clearance the NNT was 1.8 (1.7-2.0).

151 health investment in PrEP by decreasing the NNT.

152 For cardiovascular disease, the NNT was 124, 54, and 19.

153 mortality difference continues to grow, the NNT to save a life with PSA screening will decrease.

154 jointly raise the PIA, but reductions to the NNT were associated with better adherence only.

155 for the first three cutoff levels using the NNT.

156 A murine equivalent to NNT-1/BSF-3 also was identified, which shows 96% homolog

157 tes highly expressed genes are biased toward NNT instead of NNC.

158 Nicotinamide nucleotide transhydrogenase (NNT) is a mitochondrial enzyme that transfers reducing e

159 Nicotinamide nucleotide transhydrogenase (NNT) is a mitochondrial redox-driven proton pump that co

160 of nicotinamide nucleotide transhydrogenase (NNT) protein in C57BL/6J is responsible for the more sev

161 of nicotinamide nucleotide transhydrogenase (NNT) reduces NADP(+) at the expense of NADH oxidation an

162 gh nicotinamide nucleotide transhydrogenase (NNT)-deficient C57BL/6J (6J) mice are known to be highly

163 nd nicotinamide nucleotide transhydrogenase (NNT)], we selectively impaired mitochondrial respiratory

164 ty benefit of X-PCI [number needed to treat (NNT) 23 for PCI-related delay >60 min; NNT 44 for PCI-re

165 .33-0.77; P = 0.001; number needed to treat (NNT) = 21; I = 75%].

166 alculated the 5-year number needed to treat (NNT) after stratification based on the CAC score.

167 The number needed to treat (NNT) analysis indicated that 562 (95% CI 366-1,210) indu

168 cit reporting of the number needed to treat (NNT) and the absolute risk reduction (ARR) in RCTs.

169 The number needed to treat (NNT) at higher-volume providers to avoid a death was min

170 We calculated 5-year number needed to treat (NNT) by applying the benefit recorded in JUPITER to the

171 eductions (ARR) and numbers needed to treat (NNT) for 5-HT(3) antagonists, as monotherapy or as adjun

172 We used number needed to treat (NNT) for 50% pain relief as a primary measure and assess

173 lative risks and the number needed to treat (NNT) for first variceal bleed, bleed-related mortality,

174 ith vehicle, and the number needed to treat (NNT) for one patient to have their keratosis completely

175 , corresponding to a number needed to treat (NNT) of 10 (95% CI, 7 to 15), 6 (4 to 8), and 3 (2 to 5)

176 nefit subgroup had a number needed to treat (NNT) of 24 to prevent 1 CVD event/death over 5 years (ab

177 (NNS) of 1,410 and a number needed to treat (NNT) of 48 to prevent one prostate cancer death at 9 yea

178 The number needed to treat (NNT) to benefit was 41 women/babies to prevent 1 baby fr

179 sed to determine the number needed to treat (NNT) to prevent 1 ASCVD event over 5 years for each pati

180 F]) and for whom the number needed to treat (NNT) to prevent infection is lowest.

181 imated age-specific numbers needed to treat (NNT) to prevent upper gastrointestinal bleeding with rou

182 verted (PIA) and the number needed to treat (NNT) under behavioral indications of the CDC's PrEP guid

183 risk difference, the number needed to treat (NNT) was 15 (95% CI, 8-53), or equivalently 15 patients

184 The number needed to treat (NNT) was 19 for OFC and nine for each other drug.

185 The number needed to treat (NNT) was calculated by taking the inverse of the pooled

186 The number needed to treat (NNT) with FB-CBT vs FB-RT was estimated as 3.2 (95% CI,

187 The number needed to treat (NNT) with restrictive strategies to prevent serious infe

188 effects model, with numbers-needed-to-treat (NNT) calculations where appropriate.

189 Adjusted numbers needed to treat (NNTs; 95% confidence interval) to avoid composite primar

190 0.43-0.91, estimated number needed to treat [NNT 193) as was delayed prescription of antibiotics (0.5

191 70% CBT vs. 37% EDU; number needed to treat [NNT ], 3.1).

192 ARR] 2.6%, 1.5-3.7; numbers needed to treat [NNT] 39, 95% CI 27-69), deaths by suicide (OR 0.75, 0.60

193 % CI -4.09 to -0.20; number needed to treat [NNT] 47, 95% CI 25-500) and antibiotic-impregnated cathe

194 CI 1.1-3.7], p=0.03; number needed to treat [NNT] 6.6 [95% CI 3.5-81.8]).

195 ocardial infarction (number needed to treat [NNT] 63) and decrease (OR 0.36, 0.26-0.50) in myocardial

196 rval [CI] 0.53-0.74, number needed to treat [NNT] = 4) and serious liver-related adverse events such

197 with anticoagulants; number needed to treat [NNT] = 59) and greater risks of major bleeding (OR, 2.73

198 ; 95% CI, 1.06-1.68; number needed to treat [NNT], 10; 95% CI, 5-72).

199 .23 to 0.47; I2, 0%; number needed to treat [NNT], 11), and mortality (RR, 0.64; 95% CI, 0.46 to 0.89

200 ; 95% CI, 0.81-0.98; number needed to treat [NNT], 11; 95% CI, 6-54).

201 ol difference, 6.5%; number needed to treat [NNT], 15), but there was no significant reduction among

202 1.2-12.5]; P = .01; number needed to treat [NNT], 2.86).

203 , 0.65-0.83; P < .001; number need to treat [NNT], 241; 95% CI, 173-397).

204 1.16-1.95; P = .002; number needed to treat [NNT], 3.6) suggested the efficacy of CGT, and the additi

205 ; 95% CI, 0.48-0.72; number needed to treat [NNT], 6; 95% CI, 3-9).

206 0.56-0.69; P < .001; number needed to treat [NNT], 9) and 2 years (RR, 0.84; 95% CI, 0.79-0.89; P < .

207 I 0.69-0.98; p=0.02; number needed to treat [NNT]=325), with no significant heterogeneity apparent ac

208 A total of 5 patients needed to be treated (NNT-value) to prevent 1 IAP.

209 95% CI 0.53 to 0.87, 3,988 babies, 4 trials, NNT to benefit 42).

210 95% CI 0.54 to 0.87, 4,601 babies, 5 trials, NNT to benefit 46) and the neuroprotective intent analys

211 st variceal bleed was 0.48 (0.24-0.96), with NNT of 13; however, there was no effect on either bleed-

212 dL, the RR was 0.82 (95% CI, 0.70-0.97) with NNT of 20 (95% CI, 12-133).

213 Normal mice treated with NNT-1/BSF-3 also produce high amounts of Ag-specific IgE

214 -density LDL-C by 20% would provide a 5-year NNT </=50 for very high-risk patients with LDL-C >/=130

215 The estimated 5-year NNT to prevent 1 CVD event ranged from 81-130 for patien

216 coronary heart disease, the predicted 5-year NNT was 549 for CAC score 0, 94 for scores 1-100, and 24